SOURCES SOUGHT
66 -- MiSeq Reagent Kit v3 (600cycle), - NexteraŽ XT Index Kit (24 Indices, 96 Samples) and - NexteraŽ XT DNA Sample Preparation Kit (96 Samples)
- Notice Date
- 3/27/2014
- Notice Type
- Sources Sought
- NAICS
- 325413
— In-Vitro Diagnostic Substance Manufacturing
- Contracting Office
- Department of Health and Human Services, Food and Drug Administration, Office of Acquisitions and Grants Services, 3900 NCTR Road, HFT-320, Bldg 50 | Rm 421, Jefferson, Arkansas, 72079, United States
- ZIP Code
- 72079
- Solicitation Number
- 1130799
- Archive Date
- 4/18/2014
- Point of Contact
- Virginia C. House, Phone: 8705437405
- E-Mail Address
-
virginia.house@fda.hhs.gov
(virginia.house@fda.hhs.gov)
- Small Business Set-Aside
- N/A
- Description
- MARKET RESEARCH PURPOSES ONLY NOT A REQUEST FOR PROPOSAL OR SOLICITATION Part I: General Information (Introduction/Background/Scope) The U.S. Food and Drug Administration (FDA), is conducting market research to support the Center for Biologics Evaluation and Research (CBER) Laboratory of Method Development, Kensington, MD for Illumina MiSeq Reagent Kit v3 (600cycle), - Nextera® XT Index Kit (24 Indices, 96 Samples) and - Nextera® XT DNA Sample Preparation Kit (96 Samples) for use with an existing MiSeq Next-Generation Sequencer to conduct rapid preparation of samples and high throughput generation of sequencing for various viral vaccines projects in order to perform assessment of their genetic consistency and safety. This is a sources sought to determine the availability and capability of small businesses manufacturers or small business capable of supplying a U.S. made product of a small business manufacturer or producer. The associated North American Industry Classification System (NAICS) Code is 325413 In-Vitro Diagnostic Substance Manufacturing, the Small Business Size Standard is 500 employees. Part II: REQUIREMENTS: The Reagent Kit, DNA Sample Preparation Kit and Index Kit shall: • Be compatible for use with existing MiSeq Next-Generation Sequencer; • Reagent Kit (600 cycles - PE) with chemical innovations enabling fast cluster generation and low cycle times and the ability to extend paired-end read lengths to 300 pb. • DNA Sample Preparation Kit (96 Samples) and Index Kit (24 Indices, 96 Samples) allowing DNA to be simultaneously fragmented and tagged with sequencing adapters in a single tube enzymatic reaction, allowing ultra-low DNA input of a single nanogram, to support a wide array of input samples. Products offered shall include an innovative bead-based sample normalization that eliminates the need for library quantification prior to pooling and sequencing. PCR amplicons and small genomes must be easily prepared with products offered for rapid sequencing with MiSeq. Part III: Instructions to Prospective Respondents Responses to this sources sought shall unequivocally demonstrate that respondent has consumables compatible for use with MiSeq Next-Generation Sequencer, Serial No. M02269 for the intended purposes discussed above. Though the target audience is small businesses capable of providing these consumables, all interested parties may respond. At a minimum, responses shall include the following: • Business name and bio, DUNS number, business address, business website, business size status (i.e., SB, VOSB, SDVOSB, HUBZone SB, 8(a), SDB, WOSB, EDWOSB, LB), point of contact name, mailing address (if different from business address), phone number and email address; • Past performance information for sales of compatible supplies, to include description (technical literature and specifications), dollar value, client name, address, point of contact (POC), POC phone number and email address, and name of the manufacturer (to include DUNS number and size status) if not the respondent; • Descriptive literature, brochures, specifications, marketing material, etc. detailing the nature of products the responding firm is regularly engaged in providing. Note: This acquisition is intended to be a brand name requirement. Interested parties potentially offering other than MiSeq and Nextera brand name kits shall include in the response evidence/demonstration that the offered product has and will work with the existing MiSeq Next-Generation Sequencer without complications or interruptions in the research to be conducted with the kits; • If applicable, identification of the firm's GSA Schedule contract(s) by Schedule number and SINs that are applicable to this requirement; • Although this is not a request for quote, informational pricing is encouraged; • The Government encourages any comments and/or suggestions from any interested party regarding this requirement. While the Government will not respond directly to your comments and/or suggestions; we will consider them as we finalize the specifications in preparation for the forthcoming solicitation. The Government is not responsible for locating or securing any information, not identified in the response. Interested Parties must respond with capability statements which are due in person, by postal mail or email to the point of contact listed below on or before April 3, 2014 by 1:00 PM (Central Time) at the Food and Drug Administration, FDA/OO/OFBA/OAGS/DAP ATTN: Virginia C. House, 3900 NCTR Road, Bldg 50/Room 432, HFT‐320, Jefferson, AR 72079‐9502 or email virginia.house@fda.hhs.gov. Reference #1130799 in all correspondence with the point of contact listed above. Notice of Intent Responses to this sources sought announcement will assist the Government in determining whether this requirement should be set aside for small business, made available to full and open competition or procured through other than full and open acquisition procedures. Disclaimer and Important Notes This notice does not obligate the Government to award a contract or otherwise pay for the information provided in response. The Government reserves the right to use information provided by respondents for any purpose deemed necessary and legally appropriate. Any organization responding to this notice should ensure that its response is complete and sufficiently detailed to allow the Government to determine the organization's qualifications to perform the work. Respondents are advised that the Government is under no obligation to acknowledge receipt of the information received or provide feedback to respondents with respect to any information submitted. After a review of the responses received, a combined synopsis/solicitation (No. 1130799) may be published via FedBizOpps. However, responses to this notice will not be considered adequate responses to a solicitation. Confidentiality No proprietary, classified, confidential, or sensitive information should be included in your response. The Government reserves the right to use any non-proprietary technical information in any resultant solicitation(s).
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/FDA/NCTR/1130799/listing.html)
- Record
- SN03321933-W 20140329/140327234543-46edac273f8cabada01d2ced159ab5c5 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |